Tempered signal strength via low-dose MEK inhibition optimizes therapeutic performance of engineered T cells
These findings highlight moderate activation as a critical determinant of engineered T cell long-term performance. Low-dose MEKi offers a therapeutic tool for fine-tuning T cell activation and enhancing ACT efficacy.
Authors
- Leonie Rieger (ORCID: https://orcid.org/0000-0003-3263-801X)
- Priska Auf der Maur (ORCID: https://orcid.org/0000-0002-9059-8979)
- Franziska Füchsl (ORCID: https://orcid.org/0000-0001-5069-1442)
- Rupert Öllinger (ORCID: https://orcid.org/0000-0002-2292-5982)
- Florian C. Bassermann (ORCID: https://orcid.org/0000-0003-4435-2609)
- Dirk Hans Busch (ORCID: https://orcid.org/0000-0001-8713-093X)
- Angela M. Krackhardt (ORCID: https://orcid.org/0000-0002-4752-0543)
- Emmanuel Cruz
- Gabriela Zuleger (ORCID: https://orcid.org/0009-0003-6771-3005)
- S. Braun (ORCID: https://orcid.org/0009-0009-9244-1033)
- Melanie Faber
- Antonia Schwanzer
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- German Center for Infection Research (DE)
- Institute of Medical Microbiology and Hygiene (DE)
- Comprehensive Cancer Center Erlangen (DE)
- Technical University of Munich (DE)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-012800
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00